Sex hormone signature indicates gender rather than just chromosomesOctober 18, 2007Help with assigning gender could one day be at hand for intersex individuals whose genital phenotypes and sex chromosomes don't match, thanks to the discovery of a stable sex hormone signature in our cells. In an article published today in the online open access journal BMC Genomics, researchers have shown for the first time that testosterone leaves an irreversible molecular signature in cells that may provide a far more sophisticated way to look at sex than just ascertaining the presence of the Y chromosome. A team of researchers from the US and Germany were able to pinpoint the role of testosterone by comparing individuals with complete androgen insensitivity syndrome (CAIS) to people without CAIS. The findings provide a platform for future work that may lead to improved counselling for those whose gender is ambiguous. Lead researcher, Professor Paul-Martin Holterhus, of University-Hospital Schleswig-Holstein, Kiel, Germany, said: "Androgens have long lasting effects during certain sensitive stages of our genital development and this is probably true for other organs". He adds "It is currently increasingly accepted that the brain shows sex-specific development in response to presence or absence of testosterone. This affects sex specific behaviour and probably modulates gender identity." The role of androgens - especially the male-defining hormone testosterone - in sexual development has long been known. Gender programming begins in the embryo and is thought to continue throughout life, particularly during puberty. However, what's not currently known is the different roles of sex chromosome genes versus the long-term programming effects of sex hormones, namely androgens. Individuals with CAIS, which affects 1 in 20,000 people, look like normal females. But at a genetic level CAIS women have XY sex chromosomes rather than the usual XX. The condition is due to mutations in the gene coding for the androgen receptor, which means that androgen signalling doesn't work: it essentially knocks out the effect of testosterone. The researchers used skin biopsies of external genitalia to compare the gene expression of normal males and CAIS females. Analysis revealed that between males and females, 440 genes differed in their level of transcription. The activity levels of these genes form a 'signature' that they used to evaluate partial androgen insensitivity syndrome (AIS) samples and could be developed to help understand more about individual AIS cases. "Since we compared XY females with the XY males, the difference can only be explained by differences in androgen action and not by differences in sex chromosomes," explains Professor Holterhus. "Another intriguing observation is that the one normal female (with a 46,XX genotype) in our study did not differ a lot with respect to the identified genes from the XY females. This is an important reassurance for XY females because it limits the role of the sex chromosomes in gender assignment." BioMed Central |
|||||||||||||||||||||
| Related Chromosomes Current Events and Chromosomes News Articles NIH-funded researchers transform embryonic stem cells into human germ cells Researchers funded in part by the National Institutes of Health have discovered how to transform human embryonic stem cells into germ cells, the embryonic cells that ultimately give rise to sperm and eggs. A solution to Darwin's 'mystery of the mysteries' emerges from the dark matter of the genome Biological species are often defined on the basis of reproductive isolation. Ever since Darwin pointed out his difficulty in explaining why crosses between two species often yield sterile or inviable progeny (for instance, mules emerging from a cross between a horse and a donkey), biologists have struggled with this question. Common weed could provide clues on aging and cancer A common weed and human cancer cells could provide some very uncommon details about DNA structure and its relationship with telomeres and how they affect cellular aging and cancer, according to a team led by scientists from Texas A&M University and the University of Cincinnati (UC). CSHL-led team discovers rare mutation dramatically increasing schizophrenia risk An international team of researchers led by geneticist Jonathan Sebat, Ph.D., of Cold Spring Harbor Laboratory (CSHL), has identified a mutation on human chromosome 16 that substantially increases risk for schizophrenia. Standards for a new genomic era A team of geneticists at Los Alamos National Laboratory, together with a consortium of international researchers, has recently proposed a set of standards designed to elucidate the quality of publicly available genetic sequencing information. New chromosomal abnormality identified in leukemia associated with Down syndrome Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome. Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut. National Science Foundation congratulates Nobel Laureates in medicine/physiology, chemistry and economics The National Science Foundation (NSF) congratulates the 2009 Nobel laureates, particularly those who have received NSF funding over the years: Jack W. Szostak, who shared the prize in physiology or medicine; Thomas A. Steitz, who shared the prize in chemistry; and Elinor Ostrom and Oliver E. Williamson who earned the Sveriges Riksbank Prize in economic sciences in memory of Alfred Nobel 2009. Genome-wide study of autism published in Nature In one of the first studies of its kind, an international team of researchers has uncovered a single-letter change in the genetic code that is associated with autism. New treatment more than doubles survival for high risk childhood leukemia Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). More Chromosomes Current Events and Chromosomes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||